Professor Shengtao Yuan received a PhD from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in 2001. He has worked as a Professor at China Pharmaceutical University from 2015 to the present, and his research focus is tumor pharmacology. Currently, he is working on screening new drug targets, establishing the anti-tumor drug screening model, and developing innovative anti-tumor drugs. His representative works are as follows. (1) Du D, Qin M, Shi L, Liu C, Jiang J, Liao Z, Wang H, Zhang Z, Sun L, Fan H, Liu Z, Yu H, Li H, Peng J, Yuan S, Yang M, Xiong J. RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression. Oncogene. 2023 Sep 1. (2) Wang Z, Zhang Z, Li Y, Sun L, Peng D, Du D, Zhang X, Han L, Zhao L, Lu L, Du H, Yuan S, Zhan M. Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China. Acta Pharm Sin B. 2021 Jun;11(6):1526-1540.
Professor Shengtao Yuan received a PhD from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, in 2001. He has worked as a Professor at China Pharmaceutical University from 2015 to the present, and his research focus is tumor pharmacology. Currently, he is working on screening new drug targets, establishing the anti-tumor drug screening model, and developing innovative anti-tumor drugs. His representative works are as follows. (1) Du D, Qin M, Shi L, Liu C, Jiang J, Liao Z, Wang H, Zhang Z, Sun L, Fan H, Liu Z, Yu H, Li H, Peng J, Yuan S, Yang M, Xiong J. RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression. Oncogene. 2023 Sep 1. (2) Wang Z, Zhang Z, Li Y, Sun L, Peng D, Du D, Zhang X, Han L, Zhao L, Lu L, Du H, Yuan S, Zhan M. Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China. Acta Pharm Sin B. 2021 Jun;11(6):1526-1540.